** Drug developer Septerna's shares SEPN.O fall 66.6% to $4.49 premarket
** Co discontinues an early-stage trial of its experimental drug for patients with a hormonal disorder called hypoparathyroidism
** In hypoparathyroidism patients, the body does not produce enough levels of a hormone that regulates calcium and phosphorus levels in the blood
** SEPN says it stopped the trial after two participants showed unexpectedly high levels of a substance called unconjugated bilirubin, which forms when red blood cells break down
** Says it will advance other drugs with distinct and unrelated chemical structures relative to the discontinued treatment
** Stock has fallen nearly 40% since its Nasdaq debut in October
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。